• JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
 
  Bookmark and Share
 
 
Doctoral Thesis
DOI
10.11606/T.5.2013.tde-10122013-105453
Document
Author
Full name
Thiago Ferreira da Silva
E-mail
Institute/School/College
Knowledge Area
Date of Defense
Published
São Paulo, 2013
Supervisor
Committee
Pereira, Rosa Maria Rodrigues (President)
Garcia, Maria Lucia Bueno
Melo, Maria Edna de
Pinheiro, Marcelo de Medeiros
Sato, Emilia Inoue
Title in Portuguese
Avaliação da síndrome metabólica em pacientes com arterite de Takayasu
Keywords in Portuguese
Adipocinas
Arterite de Takayasu
Citocinas
Mortalidade
Síndrome X metabólica
Abstract in Portuguese
Introdução: A prevalência de Síndrome Metabólica (SM) tende a ser alta em pacientes com doenças reumáticas, sendo as doenças cardiovasculares a principal causa de óbito nestas condições. Objetivos: Determinar a prevalência de SM em pacientes com Arterite de Takayasu (AT) e sua associação com fatores de risco, níveis de adipocinas e de citocinas. Métodos: Foi realizado um estudo transversal incluindo 45 mulheres com AT e 47 controles saudáveis pareados por idade e índice de massa corporal (IMC). Resultados: A prevalência de SM (critérios da IDF/AHA) foi maior em pacientes com AT comparada aos controles (33,34 vs. 8,51%, p = 0,003). Pacientes com TA apresentaram maior frequência de hipertensão (p < 0,001) e dislipidemia (p = 0,001) e maiores níveis de insulina (p = 0,021), HOMA-IR (p = 0,024), apolipoproteína E (p = 0,029), resistina (p = 0,018) e PCR (p < 0,001) comparada aos controles saudáveis, com níveis comparáveis de adiponectina e PAI-1 (p > 0,05). Análise adicional de pacientes com AT com e sem SM revelou um maior frequência de sobrepeso/obesidade (66,66 vs. 26,66%, p = 0,022), escore de Framingham >-1 (p=0,032) e menores níveis de adiponectina (20,37+-21,16 vs. 38,64+-22,62ug/ml, p=0,022) no primeiro grupo. Não foram encontradas diferenças quanto à duração de doença, atividade, uso de glicorticóides, níveis de resistina e PAI-1 nos dois grupos de pacientes com AT (p > 0,05). Pacientes com e sem SM não demonstraram diferenças em relação aos níveis plasmáticos de citocinas (IL-12, IL-1a, IL-6 e TNFalfa). Foi evidenciada correlação de Pearson positive entre IL-6 e PCR somente nos pacientes com SM (r=0.57; p=0.050). Conclusão: Alta prevalência de SM foi observada em pacientes com AT, sendo que esta comorbidade parece identificar um subgrupo de pacientes com sobrepeso/obesidade com alto risco cardiovascular sem associação com o status de doença. Estudos longitudinais são necessários para observar o impacto do controle de fatores de risco modificáveis na qualidade de vida e sobrevida dos pacientes com AT
Title in English
Evaluation of metabolic syndrome in patients with Takayasu arteritis
Keywords in English
Adipokines
Cytokines
Metabolic syndrome X
Mortality
Takayasu arteritis
Abstract in English
Introduction: The prevalence of Metabolic Syndrome (MetS) tends to be high among rheumatic patients, and cardiovascular disease is the leading cause of death in these conditions. Objective: To determine the prevalence of MetS in Takayasu Arteritis patients (TA) and its association with risk factors and adipokines and cytokines levels. Methods: A cross sectional study was conducted in 45 consecutive TA women with 47 age- and body mass index (BMI)-matched healthy controls. Results: The prevalence of MetS (IDF/AHA criteria) was higher in TA compared to controls (33.34 vs. 8.51%, p=0.003). TA patients had higher frequency hypertension (p < 0.001), dyslipidemia (p=0.001), insulin (p=0.021), HOMA-IR (p=0.024), apoliprotein E (p=0.029), resistin (p=0.018) and CRP (p < 0.001) compared to healthy subjects, with similar levels of adiponectin and PAI-1 (p > 0.05). Further analysis of TA patients with and without MetS revealed a higher frequency of overweightness/obesity (66.66 vs. 26.66%, p=0.022), Framingham score >-1 (p=0.032), and lower adiponectin levels (20.37+-21.16 vs. 38.64±22.62ug/ml, p=0.022) in the former group. No differences were found regarding disease duration, activity, glucocorticoid use, resistin and PAI-1 levels in these two groups of TA patients (p > 0.05). Patients with and without MetS showed no differences respect to cytokines levels (IL-12, IL-1a, IL-6 and TNFalfa). IL-6 had a positive Pearson correlation with CRP only in TA patients with MetS (r=0.57; p=0.050). Conclusion: A high prevalence of MetS was observed in TA patients and this comorbidity seems to identify a subgroup of overweight/obese patients with high cardiovascular risk without a significant association with disease status. Further longitudinal studies are necessary to observe the impact of controlling this modifiable risk factor in the quality of life and survival of TA patients
 
WARNING - Viewing this document is conditioned on your acceptance of the following terms of use:
This document is only for private use for research and teaching activities. Reproduction for commercial use is forbidden. This rights cover the whole data about this document as well as its contents. Any uses or copies of this document in whole or in part must include the author's name.
Publishing Date
2013-12-10
 
WARNING: Learn what derived works are clicking here.
All rights of the thesis/dissertation are from the authors
Centro de Informática de São Carlos
Digital Library of Theses and Dissertations of USP. Copyright © 2001-2019. All rights reserved.